ITC Probes Impact of Revoking China PNTR and Biotech Practices

STR Trade Report

Published March 2nd, 2026

Detected March 1st, 2026

Summary

The International Trade Commission (ITC) has launched two fact-finding investigations. One assesses the economic impact of revoking China's Permanent Normal Trade Relations (PNTR) treatment, with input due April 13. The second probe examines Chinese state support and pricing practices in the biotechnology sector.

View original document View source feed page

What changed

The International Trade Commission (ITC) is initiating two significant fact-finding investigations. The first will assess the potential impact on the U.S. economy, industry, and product sourcing over a six-year period if China's Permanent Normal Trade Relations (PNTR) treatment is revoked. This investigation will also examine an alternative scenario involving a five-year phase-in of tariffs on national security products. The second probe will specifically investigate Chinese state support and pricing practices within the biotechnology sector, including genomic sequencing, synthetic biology, and active pharmaceutical ingredient manufacturing, to determine their effect on U.S. market share and competitiveness.

Interested parties are invited to submit input for the PNTR investigation by April 13. The ITC will hold a hearing for the biotechnology probe on May 27-28, with various submission deadlines for briefs and statements preceding it. While these are fact-finding investigations and do not immediately impose new regulations or penalties, the findings could inform future policy decisions regarding trade with China and its impact on U.S. industries. Companies involved in trade with China or the biotechnology sector should consider submitting relevant data and analysis to the ITC.

What to do next

Submit input to the ITC regarding the economic impact of revoking China's PNTR treatment by April 13, 2026.
Consider submitting data and analysis for the biotechnology sector probe, noting the hearing dates of May 27-28, 2026, and associated deadlines for briefs and statements.

Source document (simplified)

March 2, 2026 // Trade Report

New Probes to Assess Potential Revocation of China PNTR Treatment, Chinese Biotech Practices

Subscribe to daily updates Subscribe to daily updates

Go Back to Trade Report
The International Trade Commission will accept input from interested parties through April 13 as part of a new factfinding investigation on the impact on the U.S. economy, U.S. industry, and product sourcing over a six-year period of revoking permanent normal trade relations (PNTR) treatment for all products of China. Due to the accelerated timeline of this investigation, the ITC does not plan to hold a public hearing in connection with the preparation of this report.

The ITC intends to cover the following topics, to the extent practicable:

the results of the agency’s investigation and analysis, including detailed information, to the extent practicable, on U.S. trade, production, and prices in the industries that could be directly and most affected by the imposition of rates of duty in column 2 of the HTSUS on products of China; and
an examination of an alternative scenario where Congress revokes PNTR treatment with a five-year phase-in of tariffs on a subset of national security products.

Revoking PNTR treatment with respect to Chinese goods would result in a substantial increase in U.S. import duties for those products, as column 2 duty rates are typically markedly higher than regular (column 1) rates.

The ITC has launched a separate probe into Chinese state support and pricing practices in the biotechnology sector and will assess how these practices may be affecting the market share and competitiveness of the U.S. industry. To the extent practicable, this report will:

review the extent to which Chinese state support and pricing practices in the biotech sector, including genomic sequencing, synthetic biology, and active pharmaceutical ingredient manufacturing, may be affecting U.S. market share and competitiveness; and
outline the ITC’s findings and identify impacts to U.S. biotech producers and service providers.

The ITC will hold a hearing in connection with this investigation May 27-28. Requests to appear at the hearing are due by May 11, prehearing briefs and statements must be submitted by May 14, electronic copies of hearing oral arguments are due by May 20, posthearing briefs are due by June 11, and all other written submissions must be filed by July 17.

ST&R: International Trade Law & Policy

Since 1977, we have set the standard for international trade lawyers and consultants, providing comprehensive and effective customs, import and export services to clients worldwide.